Antibody Conjugates-Recent Advances and Future Innovations

Area of Science:

• Biotechnology
• Pharmacology
• Oncology

Background:

• Monoclonal antibodies have transitioned from research tools to significant therapeutics over 30 years.
• Protein therapeutics face limitations, being unable to target intracellular antigens.
• Advances in antibody engineering enable antibody conjugates for targeted drug delivery.

Purpose of the Study:

• To review the progress and challenges in antibody conjugate development.
• To highlight key aspects of antibody conjugation, linker-payload chemistry, and ADME.
• To discuss lessons learned from oncology antibody conjugates and future directions.

Main Methods:

• Review of scientific literature on antibody conjugation and drug delivery.
• Analysis of advancements in protein engineering, formulation, and delivery systems.
• Examination of linker-payload chemistry and novel payload classes.

Main Results:

• Antibody conjugates leverage antibody targeting for potent small molecule delivery.
• Early antibody conjugates showed limited clinical success.
• Significant progress has been made in conjugation techniques, linker stability, and payload diversity.

Conclusions:

• Antibody conjugates represent a promising therapeutic modality by combining antibody specificity with potent drug payloads.
• Overcoming challenges in conjugation, linker-payload design, and ADME is crucial for clinical success.
• Future innovations aim to expand the application of antibody conjugates to new therapeutic areas beyond oncology.